In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 211 to 220 of 300

TitleTypeExpected publication date
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]Technology appraisal guidance
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidanceTBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidanceTBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Technology appraisal guidance
Pridopidine for treating Huntington's disease [ID6525]Technology appraisal guidanceTBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]Technology appraisal guidanceTBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All